SCHEMBL1118010

SCHEMBL1118010

Cc1cc(B(O)OC(C)(C)C(C)(C)O)ccn1

nearest known ligand 0.36

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
UHRF1 Q96T88 1/20 0.36
DYRK1A Q13627 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12816668 0.84
SCHEMBL16012071 0.83 RECQL (0.34)
SCHEMBL15311827 0.83 MKNK1 (0.32)
SCHEMBL1257059 0.83 NOS3 (0.38) DYRK1A
SCHEMBL992046 0.82 LOX (0.37)
SCHEMBL16008776 0.81 CHRNA7 (0.30)
SCHEMBL12816056 0.81
SCHEMBL15658168 0.81 LOXL2 (0.36)
SCHEMBL2146734 0.80
SCHEMBL12814866 0.80 PDK1 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12528819-B2 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment AGENEBIO, INC. (US) 2026-01-20 US disclosed
US-20250188053-A1 PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF ROR-GAMMA AND OTHER USES REATA PHARMACEUTICALS, INC. (US) 2025-06-12 US disclosed
US-12291535-B2 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment AGENEBIO, INC. (US) 2025-05-06 US disclosed
WO-2024153067-A1 HETEROCYCLE-SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE, PHARMACEUTICAL COMPOSITION, USE, AND PREPARATION METHOD THEREFOR 上海海雁医药科技有限公司 2024-07-25 WO disclosed
US-12024525-B2 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment AGENEBIO, INC. (US) 2024-07-02 US disclosed
CN-112601749-B Benzodiazepine derivatives, compositions and methods for treating cognitive impairment 艾吉因生物股份有限公司 2024-03-26 CN disclosed
CN-112409363-B Benzodiazepine derivatives, compositions and methods for the treatment of cognitive impairment 艾吉因生物股份有限公司 2023-11-14 CN disclosed
CN-116640143-A Benzodiazepine derivatives, compositions and methods for treating cognitive impairment 艾吉因生物股份有限公司 2023-08-25 CN disclosed
CN-111909083-B Inhibitors of histone demethylase 赛尔基因昆蒂赛尔研究公司 2023-08-15 CN disclosed
EP-3555100-B1 BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT AGENEBIO INC (US) 2023-05-10 EP disclosed
US-20110281881-A1 NOVEL SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS GAMMA SECRETASE MODULATORS CELLZOME LIMITED (GB) 2011-11-17 US disclosed
US-20110251186-A1 Amino-Oxazines and Amino-Dihydrothiazine Compounds as Beta-Secretase Modulators and Methods of Use AMGEN INC. (US) 2011-10-13 US disclosed
WO-2011115928-A1 AMINO -DIHYDROOXAZINE AND AMINO - DIHYDROTHIAZINE SPIRO COMPOUNDS AS BETA - SECRETASE MODULATORS AND THEIR MEDICAL USE AMGEN INC. (US) 2011-09-22 WO disclosed
WO-2011086099-A1 NOVEL SUBSTITUTED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) 2011-07-21 WO disclosed
WO-2011086098-A1 NOVEL SUBSTITUTED BICYCLIC TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) 2011-07-21 WO disclosed
US-20110118208-A1 Thiazolyl-Dihydro-Indazoles BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-05-19 US disclosed
EP-2280982-A1 THIAZOLYL-DIHYDRO-INDAZOLES Boehringer Ingelheim International GmbH (DE) 2011-02-09 EP disclosed
WO-2010089292-A1 NOVEL SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS GAMMA SECRETASE MODULATORS ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) 2010-08-12 WO disclosed
US-20100120761-A1 Bicyclic Heterocyclic Compounds as FGFR Inhibitors ASTEX THERAPEUTICS LIMITED (GB) 2010-05-13 US disclosed
WO-2009112565-A1 THIAZOLYL-DIHYDRO-INDAZOLES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281881-A1 NOVEL SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS GAMMA SECRETASE MODULATORS BACE1, BACE2, APH1A UHRF1 3128/4885DYRK1A 4565/4885
US-12024525-B2 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment GRM5, GABRA5, GABRE UHRF1 4101/4885DYRK1A 4484/4885
US-12528819-B2 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment GABRA5, GRM5, GABRE UHRF1 3695/4885DYRK1A 4014/4885
US-20110251186-A1 Amino-Oxazines and Amino-Dihydrothiazine Compounds as Beta-Secretase Modulators and Methods of Use BACE1, APP, BACE2 UHRF1 2247/4885DYRK1A 2095/4885
US-20110118208-A1 Thiazolyl-Dihydro-Indazoles MKI67, CYP11B1, IGF1R UHRF1 2842/4885DYRK1A 722/4885
US-20250188053-A1 PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF ROR-GAMMA AND OTHER USES RORC, RORB, RORA UHRF1 4183/4885DYRK1A 4077/4885
US-20100120761-A1 Bicyclic Heterocyclic Compounds as FGFR Inhibitors FGFR3, FGFR1, FGFR2 UHRF1 2178/4885DYRK1A 1119/4885
US-12291535-B2 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment GABRA5, GRM5, GABRA1 UHRF1 2998/4885DYRK1A 3509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.